Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

This study is testing evenamide, an experimental drug that reduces excess glutamate (a brain chemical) in people with schizophrenia who have not responded to other antipsychotic treatments. It is added on top of the patient's current medications. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of schizophrenia - You have tried multiple antipsychotic medications and they haven't worked well enough - You are currently taking at least one antipsychotic medication at a recommended dose - Your symptoms are at least moderately severe **You may NOT be eligible if...** - You have a different primary psychiatric diagnosis (e.g., bipolar disorder, schizoaffective disorder) - You have had a substance use disorder in the past 3 months - You have epilepsy or have had a seizure in the past year - You have attempted suicide in the past 2 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.